This article is more than 5 years old. Information may no longer be current.

VIDEO: Expert discusses label change for Trintellix

NEW YORK — Gregory Mattingly, MD, psychiatrist and associate clinical professor at Washington University School of Medicine, spoke with Healio Psychiatry at the American Psychiatric Association Annual Meeting about cognition in relation to mood disorders.

He discussed a landmark label update for Trintellix (vortioxetine; Takeda, H. Lundbeck) that now includes information on the cognitive aspects for treating patients with mood disorders, particularly depression. Specifically, the updated label addresses not just depressive symptoms, but also processing speed, which plays a vital role in cognition.

Disclosures: Mattingly reports consulting from Alkermes, Allergan, Forum Pharmaceuticals, Lundbeck, Merck & Co., Otsuka Pharmaceuticals, Perdue Pharmaceuticals, Rhodes Pharmaceuticals, Shire, Sunovion Pharmaceuticals Inc., Takeda and Vanda. He reports honoraria from Allergan, Alkermes, Lundbeck, Merck, Neos, Otsuka and Shire. He also reports grant/research support from Alcobra Ltd., Alkermes, Alkili Interactive, Allergan, Boehringer Ingelheim Pharmaceuticals, Forum Pharmaceuticals, Janssen, Medgenics, NLS-1 Pharma AG, Reckitt Benckiser, Supernus and Takeda.

Editor’s note: This story was updated on May 16, 2018 to include edits from the speaker.